Keytruda Plus Chemo Improves Complete Response Rate in Breast Cancer

The combination of Keytruda to neoadjuvant chemotherapy, followed by Keytruda in combination with endocrine therapy improved pathologic response rates for patients with early-stage, high-risk, estrogen receptor (ER)–positive/HER2-negative breast cancer.

Related Keywords

China ,San Antonio ,Texas ,United States ,Baylor University ,Dallas ,Joyce Oshaughnessy ,Breast Cancer Research Program At Texas Oncology ,Incorporating Keytruda ,Antonio Breast Cancer Symposium ,Eastern Europe ,Joyceo Shaughnessy ,Celebrating Women Chair ,Breast Cancer Research ,Baylor University Medical Center ,Breast Cancer Research Program ,Texas Oncology ,Within China ,News ,Breast Cancer ,Sabcs ,Conference ,